Silverback Therapeutics, Inc.·4

Feb 2, 5:19 PM ET

Piazza Jonathan 4

4 · Silverback Therapeutics, Inc. · Filed Feb 2, 2022

Insider Transaction Report

Form 4
Period: 2022-02-01
Piazza Jonathan
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2022-02-01+67,50067,500 total
    Exercise: $4.85Exp: 2032-01-31Common Stock (67,500 underlying)
  • Award

    Common Stock

    2022-02-01+11,25025,534 total
  • Award

    Stock Option (right to buy)

    2022-02-01+42,75042,750 total
    Exercise: $4.85Exp: 2032-01-31Common Stock (42,750 underlying)
Footnotes (4)
  • [F1]The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]Includes 2,054 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2021 and 326 shares acquired under the ESPP on December 31, 2021.
  • [F3]The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022.
  • [F4]25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION